@article{8b2cc92d4b53409890208c7d9b97f8e7,
title = "Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study",
abstract = "Objective.: A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with advanced or recurrent endometrial cancer who had received one prior platinum therapy. Methods.: Eligible patients were to have measurable disease and one prior chemotherapy regimen which could include cisplatin or carboplatin. Oxaliplatin 130 mg/m2 was administered intravenously over 2 h. This treatment was repeated every 21 days until progression of disease or adverse effects prohibited further therapy. Results.: Fifty-four patients were entered on study, of which 52 were eligible and 50 had had prior platinum therapy. The overall response rate was 13.5%, with three patients (5.8%) achieving a complete response and four patients (7.7%) achieving a partial response. Median duration of response was 10.9+ (range: 4.1-50.3+) months. Stable disease was reported in 15 (28.8%) patients, with an associated median duration of 5.4 (range: 2.2-19.6) months. Drug-related toxicities consisted of anemia, nausea and vomiting, and neurotoxicity. Conclusions.: Oxaliplatin at the dose and schedule employed has limited activity in patients with advanced or recurrent endometrial carcinoma who have had previous platinum therapy.",
author = "Fracasso, {Paula M.} and Blessing, {John A.} and Molpus, {Kelly L.} and Adler, {Lisa M.} and Sorosky, {Joel I.} and Rose, {Peter G.}",
note = "Funding Information: This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517) and a Clinical Oncology Career Development Award from the American Cancer Society to PMF. The following member institutions participated in this study: Abington Memorial Hospital; University of Alabama at Birmingham; University of California Medical Center at Irvine; Case Western Reserve University; University of Chicago; University of Cincinnati; The Cleveland Clinic Foundation; Community Clinical Oncology Program; Colorado Gynecologic Oncology Group P.C.; Columbus Cancer Council; Cooper Hospital/University Medical Center; Fox Chase Cancer Center; Milton S. Hershey Medical Center; University of Iowa Hospitals and Clinics; University of Minnesota Medical School; University of Mississippi Medical Center; University of North Carolina School of Medicine; University of Oklahoma; Rush-Presbyterian—St. Luke's Medical Center; State University of New York at Stony Brook; SUNY Downstate Medical Center; Thomas Jefferson University Hospital; Tampa Bay Cancer Consortium; Tufts-New England Medical Center; Wake Forest University School of Medicine. ",
year = "2006",
month = nov,
doi = "10.1016/j.ygyno.2006.03.043",
language = "English (US)",
volume = "103",
pages = "523--526",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",
}